

# City of Hope-BD

## PGY2 Medication-Use Safety and Policy



The PGY2 pharmacy residency in Medication-Use Safety and Policy (MUSP) is a one-year advanced training program designed to prepare the resident to assume a leadership role as a subject matter expert in implementing medication-use system improvements to enhance patient safety, compliance and quality.

### **PGY2 PROGRAM PURPOSE**

PGY2 residency programs build upon Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency training to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives for advanced practice areas. Residents who successfully complete PGY2 residency programs are prepared for advanced patient care or other specialized positions, and board certification in the advanced practice area, if available.

### **CITY OF HOPE**

Founded in 1913, City of Hope is a world-renowned research, patient care and educational facility recognized by *U.S. News & World Report* as one of "America's Best Hospitals" for cancer treatment. We are one of a select group of National Cancer Institute-designated Comprehensive Cancer Centers and a founding member of the National Comprehensive Cancer Network.

Our Los Angeles County inpatient and ambulatory care facility is in Duarte, California. This lush 110-acre campus boasts beautiful landscapes and breathtaking views of the panoramic vistas of the Angeles National Forest. The City of Hope Los Angeles Enterprise includes an extensive network of community practice sites throughout Los Angeles, Riverside, Ventura, and San Bernardino counties.

City of Hope Orange County brings specialized cancer care and clinical trials to the region. Located on an 11-acre Irvine campus, Lennar Foundation Cancer Center is the equivalent to four football fields of cancer research and treatment, offering comprehensive oncology services and highly specialized programs. In addition, patients can also access advanced care at five regional clinics throughout Orange County and Long Beach.

The City of Hope Pharmacy Enterprise is committed to delivering best-in-class pharmaceutical care. Our reputation for groundbreaking discoveries, innovative treatments and compassionate patient care makes us an excellent place for highly motivated pharmacists interested in establishing an exceptional career in a progressive clinical setting.

### **BECTON, DICKINSON & COMPANY (BD)**

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers.

### **PROGRAM OVERVIEW**

The PGY2 resident will:

- Critically evaluate and identify vulnerabilities in the 11 elements of medication-use.
- Cultivate expertise in regulatory and accreditation requirements.
- Apply performance improvement principles (e.g., PDSA, Lean).
- Gain global industry and health-system experiences in automation and medication management technology optimization.
- Design health economics and outcomes research to generate real-world evidence.
- Direct teams and actively participate in local and global policy, safety, and risk management committees.
- Complete a Teaching Certificate through Chapman University School of Pharmacy (optional).

### **APPLICATION PROCESS**

Submit letter of intent, transcript, CV, and 3 letters of recommendation via PhORCAS by January 10th.

# Medication-Use Safety and Policy Residency (continued)



## REQUIRED LEARNING EXPERIENCES

### MEDICATION SAFETY I & II

These two learning experiences will introduce the resident to foundational concepts that will be applied to augmenting safeguards within the medication-use system.

### ADULT HEMATOLOGY

The resident will focus on safety considerations in regimens used for AML, ALL, stem cell transplant, and CAR T-cell therapy.

### INPATIENT OPERATIONS

This learning experience focuses on enhancing safety and quality within inpatient workflows and drug delivery processes.

### COMMUNITY CLINIC

The resident will be exposed to the unique compliance and safety issues of community infusion practice at Lennar Foundation Cancer Center.

### COMPLIANCE AND REGULATORY

This rotation will provide an understanding of compliance with accreditation standards and regulations, including survey readiness and constructing survey response plans.

### CLINICAL INFORMATICS

The resident will evaluate electronic health record medication builds, order sets and chemotherapy treatment plans for design improvements to maximize safety and Clinical Pathways enhancement.

### AUTOMATION AND TECHNOLOGY

This rotation will provide in-depth exposure to medication management technologies (e.g., infusion pumps with dose error reduction software, medication barcode scanning, automated dispensing cabinets, data and analytics) across the continuum of care.

### FORMULARY MANAGEMENT AND DRUG USE POLICY

This learning experience is centered around formulary management principles, evidence-based reviews, and drug shortage/recall management.

### MEDICATION USE SAFETY HEALTH ECONOMICS AND OUTCOMES RESEARCH

This rotation will provide the resident with experience conducting systematic literature evaluations, designing real-world evidence, evaluating financial models, and identifying research best practices.

## LONGITUDINAL LEARNING EXPERIENCES

### MEDICATION SAFETY LEADERSHIP

The resident will participate in various multidisciplinary committees and activities throughout the year to gain a comprehensive understanding of the medication-use process and system improvements.

### RESEARCH PROJECT

The resident will complete a joint City of Hope and BD research project aimed at improving the medication-use system.

### GLOBAL SAFETY AND COMPLIANCE

The resident will participate in pre- and post-market medical technology risk management activities including failure mode and effects analyses (FMEAs) and root cause analyses (RCAs).

## PROGRAM CONTACTS

Wyndie Tse, Pharm.D., M.H.A.  
Director, Medication Safety and Quality Residency Program  
[wtse@coh.org](mailto:wtse@coh.org)

Craig Greszler, Pharm.D., M.B.A., B.C.S.C.P.  
Senior Manager, Medical Affairs (BD)  
[craig.greszler@bd.com](mailto:craig.greszler@bd.com)